Anti-Ebolavirus; GP (Clone EBOV-548)-Purified No Carrier Protein
Produktgrößen
250µg
£583,00
12-8207-250UG
1 mg
£812,00
12-8207-1MG
Über dieses Produkt
- SKU:
- 12-8207
- Anwendung:
- Electron Microscopy
- translate.label.attr.clone:
- EBOV-548
- Klonalität:
- Monoclonal
- Weitere Details:
- Specificity: EBOV-548 activity is directed against the glycan cap of the GP1 subunit of Zaire ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV) glycoprotein. Antigen Distribution: Ebola virus glycoprotein is a surface protein expressed on the virus envelope. Background: Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90%1. Three Ebola species are responsible for lethal outbreaks: Zaire ebolavirus (EBOV); Bundibugyo ebolavirus (BDBV); and Sudan ebolavirus (SUDV). The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell; endosomal entry; and membrane fusion1. GP is composed of two subunits; GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop; transmembrane domain; and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus1;2;3;4. EBOV-548 is a pan-EBOV-neutralizing mAb isolated from a survivor of the EBOV 2013-2016 outbreak2. Hybridomas were generated from human peripheral blood mononuclear cells. EBOV GP-reactive memory B cells were labeled with recombinant EBOV GP protein; purified by FACS; bulk expanded on NIH 3T3 cells; bulk fused with MFP-2 myeloma cells; and screened for neutralizing activity against live and/or recombinant EBOV; BDBV; and SUDV GP. EBOV-548 reacts to all three species GPs and neutralizes EBOV and BDBV. EBOV-548 recognizes intact but not cleaved GP. EBOV-548 was identified in a study designed to develop a cooperative two-antibody cocktail with EBOV-5202;4. When paired; EBOV-548 and EBOV-520 have synergistic activity for GP binding and virus neutralization2. This is achieved mechanically. EBOV-548 binds to the glycan cap in a manner that destabilizes the GP trimer; displacing the ?17-?18 loop. As a result; the glycan cap is pulled back; facilitating EBOV-520 binding and enhancing neutralization. The cooperative effect is dependent on EBOV-548 concentration. When administered together in vivo; EBOV-548 potentiates protection by EBOV-520 against SUDV; with 50% of mice surviving treatment; while only 10% survive with EBOV-520 alone.
- Isotyp:
- Human IgG1
- Aufreinigung:
- Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are pu
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- This antibody may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at
- Hersteller:
- Abeomics
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules
- Datenblatt des Herstellers:download_pdf.php